BTIG analyst Justin Zelin downgraded Lyra Therapeutics (NASDAQ: LYRA) from Buy to Neutral.The analyst comments "This morning, Lyra announced that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE